3-Deazaneplanocin A

3-Deazaneplanocin A

• CAS Number: 102052-95-9
• UNSPSC Description: 3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor[1][2]. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity[6][7].
• Target Antigen: Histone Methyltransferase; Orthopoxvirus
• Type: Reference compound
• Related Pathways: Anti-infection;Epigenetics
• Field of Research: Cancer; Infection
• Assay Protocol: https://www.medchemexpress.com/3-deazaneplanocin-a.html
• Purity: 99.97
• Solubility: H2O : 100 mg/mL (ultrasonic)
• Smiles: O[C@@H]1[C@H](O)C(CO)=C[C@H]1N2C=NC3=C2C=CN=C3N
• Molecular Weight: 262.26
• References & Citations: [1]Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009, 114(13), 2733-2743.|[2]Avan A, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012 Aug;11(8):1735-46.|[3]Kikuchi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78(2):138-43.|[4]Sun F, et al. Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus?. Eur J Pharm Sci. 2015 Sep 18;77:290-302.|[5]Siddiqi FS, et al. The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes. J Am Soc Nephrol. 2016 Jul;27(7):2021-34.|[6]Noriko Uchiyama, et al. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. Eur J Pharmacol. 2017 Oct 5;812:138-146.|[7]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.bioRxiv. 2024 July 27.|Cancers (Basel). 2022 Jul 23;14(15):3600.|Cell Death Dis. 2020 Oct 23;11(10):906.|Cell Death Discov. 2024 Jul 28;10(1):341.|Cell Rep. 2023 May 23;42(6):112550.|Cell Reprogram. 2017 Dec;19(6):363-371.|Cells Tissues Organs. 2021 Jan 18;1-9.|Genes. 2024 Sep 13.|Int Immunopharmacol. 2022 Feb 19;106:108612.|J Am Soc Nephrol. 2016 Jul;27(7):2021-34. |J Immunother Cancer. 2019 Nov 14;7(1):300. |J Mol Cell Cardiol. 2019 Oct;135:119-133.|Lab Invest. 2021 Mar 10.|Nat Commun. 2021 Feb 23;12(1):1237.|Patent. US20180263995A1.|Research Square Preprint. 2020 May.|Research Square Print. September 13th, 2022.|Apoptosis. 2020 Oct;25(9-10):697-714.|Biochem Biophys Res Commun. 2018 Sep 10;503(3):2061-2067.|bioRxiv. 2023 Apr 21.|bioRxiv. 2024 May 18.|Cell Signal. 2023 Dec 30:115:111029.|Exp Mol Pathol. 2020 Feb;112:104344.|J Pharmacol Exp Ther. 2019 Sep;370(3):490-503.|Nat Commun. 2022 Jan 10;13(1):12.|Università degli Studi di CAGLIARI. Dipartimento di Scienze Biomediche. 2021 May.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported